---
title: "三生制藥 (01530.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01530.HK.md"
symbol: "01530.HK"
name: "三生制藥"
industry: "生物技術"
---

# 三生制藥 (01530.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.3sbio.com](https://www.3sbio.com) |

## Company Profile

投資控股,及本集團主要在中國從事開發、生產、營銷及銷售生物醫藥產品。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:10.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.91% |  |
| Net Profit YoY | 42.42% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.32 |  |
| Dividend Ratio | 1.01% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 59.38B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 9.84B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 15.36% | A |
| Profit Margin | 25.99% | A |
| Gross Margin | 85.31% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.91% | B |
| Net Profit YoY | 42.42% | B |
| Total Assets YoY | 1.37% | C |
| Net Assets YoY | 14.34% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 384.72% | C |
| OCF YoY | 7.91% | B |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.38 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 20.51% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 三生制藥",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "15.36%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "25.99%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "85.31%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.91%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "42.42%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.37%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "14.34%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "384.72%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "7.91%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "20.51%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百濟神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信達生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制藥 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奧賽圖-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和鉑醫藥-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 23.18 | 6/70 | 29.55 | 25.51 | 13.60 |
| PB | 3.35 | 21/70 | 4.20 | 3.62 | 1.80 |
| PS (TTM) | 6.02 | 15/70 | 7.44 | 6.38 | 3.04 |
| Dividend Yield | 1.00% | 4/70 | 2.00% | 0.95% | 0.81% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T16:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 9 | 64% |
| Overweight | 4 | 29% |
| Hold | 1 | 7% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 23.62 |
| Highest Target | 48.84 |
| Lowest Target | 25.21 |

## References

- [Company Overview](https://longbridge.com/en/quote/01530.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01530.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01530.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.